Fulcrum Therapeutics Inc. (NASDAQ:FULC) finished Thursday with a subtraction of -$0.67 to close at $5.41, a downside of -11.02 percent. An average of 18,570,441 shares of common stock have been traded in the last five days. There was a gain of $1.45 in the past week, and it reached a new high 12 times over the past 12 months. The last 20 days have seen an average of 5,045,360 shares traded, while the 50-day average volume stands at 2,501,790.
FULC stock has increased by 45.43% in the last month. The company shares reached their 1-month lowest point of $3.50 on 07/27/23. With the stock rallying to its 52-week high on 01/13/23, shares of the company touched a low of $2.25 and a high of $15.00 in 52 weeks. It has reached a new high 9 times so far this year and lost -25.69% or -$1.87 in price. In spite of this, the price is down -63.93% from the 52-week high.
Insider Transactions
FULC stock investors should be aware that Fulcrum Therapeutics Inc. (FULC) stock had its last reported insider trading activity 107 days ago on May 10. In this transaction, the insider spent $695. Interim President & CEO, Gould Robert J, disposed of 6,766 shares at a price of $15.00 on Jan 13. The insider now owns more than $101,490 worth of shares.
Valuation Metrics
Fulcrum Therapeutics Inc. (FULC) stock’s beta is 1.94. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 112.91, the price-to-book (PB) ratio at 1.21.
Financial Health
The quick ratio of Fulcrum Therapeutics Inc. for the three months ended June 29 was 19.10, and the current ratio was 19.10, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Fulcrum Therapeutics Inc.’s EBITDA margin for the year ending June 29 is -1730.05%. Its gross profit as reported stood at $118.9 million compared to revenue of $6.34 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Fulcrum Therapeutics Inc.’s return on assets was -35.90%.
Earnings Surprise
In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$23.78 million in the quarter, while revenues of -$24.78 million were shrunk -43.27%. The analyst consensus anticipated Fulcrum Therapeutics Inc.’s latest quarter earnings to come in at -$0.44 per share, but it turned out to be -$0.38, a 13.60% surprise. For the quarter, EBITDA amounted to -$26.73 million. Shareholders own equity worth $61.82 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Fulcrum Therapeutics Inc. (FULC) price momentum. RSI 9-day as of the close on 24 August was 67.22%, suggesting the stock is Neutral, with historical volatility in this time frame at 190.39%.
As of today, FULC’s price is $4.95 +36.62% or $1.45 from its 5-day moving average. FULC is currently trading +52.82% higher than its 20-day SMA and +89.82% higher than its 100-day SMA. However, the stock’s current price level is +71.75% above the SMA50 and -6.40% below the SMA200.
The stochastic %K and %D were 72.25% and 62.12%, respectively, and the average true range (ATR) was 0.61. With the 14-day stochastic at 63.54% and the average true range at 0.50, the RSI (14) stands at 66.70%. The stock has reached 1.06 on the 9-day MACD Oscillator while the 14-day reading was at 1.22.
Analyst Ratings
H.C. Wainwright upgraded Fulcrum Therapeutics Inc. (NASDAQ: FULC) to a a Buy rating in its most recent analyst report. Previously, the stock was rated as a Neutral. The consensus rating for Fulcrum Therapeutics Inc. (FULC) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell FULC, while 1 suggest investors hold. There are 1 analyst who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 5 others rate it as a “buy”.
What is FULC’s price target for the next 12 months?
Analysts predict a range of price targets between $4.00 and $16.00, with a median target of $8.00. Taking a look at these predictions, the average price target given by analysts for Fulcrum Therapeutics Inc. (FULC) stock is $9.57.
